Korify Capital

Wonder Brands partners with successful digital brands in Latin America, investing significantly to boost growth. It provides value through technology, digital marketing, supply chain, administration support, enabling brands to expand reach and diversify products.

AERA Health is a start-up focused on preventive health technology, aiming to inspire the next generation of healthcare professionals. The company has developed a comprehensive medical platform that combines a data-driven approach with preventative measures to enhance overall health and well-being. AERA Health's software provides consumers with access to personalized diagnoses and therapies, promoting an innovative hybrid model in healthcare delivery. By motivating healthcare professionals to realize their full potential, AERA Health seeks to make a positive impact on the health sector and improve patient outcomes.

Bionomics is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for central nervous system disorders and cancer in Australia and the United States. Its lead program, BNC210, is a selective negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor studied for anxiety, panic, agitation, and post-traumatic stress disorder. The company’s portfolio also includes BNC105, a vascular disrupting agent for solid tumors; BNC101, a monoclonal antibody targeting cancer stem cells; and BNC375, a compound aimed at cognitive impairment in Alzheimer's disease. Bionomics also develops ionX, a genomics platform that supports its drug discovery efforts, and maintains strategic partnerships with industry collaborators to advance its therapies.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

FORME, founded in 2020 and based in Los Angeles, California, offers an integrated home fitness platform that focuses on sports and fitness instruction. The company provides interactive wellness and strength training sessions, allowing customers to engage in personalized workouts from the comfort of their homes. In addition to fitness training, FORME’s health coaching services include guidance on nutrition, recovery, sleep, and various lifestyle aspects. Revenue is generated through the sale of connected fitness products, membership fees, and personal training services, positioning FORME as a comprehensive solution for individuals seeking to enhance their fitness and overall well-being.

Gameto is a biotechnology company focused on advancing female reproductive health through innovative therapies. Recognizing the significant lack of treatment options in this underserved area, Gameto employs cutting-edge scientific techniques to develop solutions that enhance the quality of life for women. The company utilizes cellular engineering to create a platform that produces engineered ovarian and endometrial cell lines capable of mimicking the functions of natural cells, including hormone production and response. This platform underpins a portfolio of cellular therapeutics aimed at addressing various female reproductive diseases. Gameto's first initiative, Fertilo, targets improvements in in vitro fertilization (IVF) and egg freezing processes, striving to make them shorter, safer, and more effective. Additionally, the company is developing Deovo, an organoid model of the female reproductive system, and Ameno, a cell-based therapy designed to mitigate health issues related to primary ovarian insufficiency and menopause. Through these efforts, Gameto aims to transform the landscape of female reproductive health care.

AMZSCALE specializes in comprehensive brand-building services for Amazon. Their team comprises experienced eCommerce experts who have successfully launched, grown, and sold their own Amazon brands. They offer end-to-end support, including product research, supplier sourcing, listing creation, fulfillment coordination, and advertising management.

Storypod fosters children's love for learning via screen-free, interactive audio content. Its IoT platform delivers stage-based, adaptive educational materials, supporting early childhood cognitive development.

Cambrian BioPharma specializes in developing innovative therapeutics aimed at extending healthspan, the period of life spent in good health. As a Distributed Development Company (DisCo), it focuses on advancing scientific breakthroughs targeting biological drivers of aging, initially treating specific diseases and later deploying these interventions preventatively to enhance overall quality of life.

Olsam Group is a commerce company that acquires and operates top Amazon third-party and other direct-to-consumer eCommerce brands. It employs a technology-driven approach, focusing on scaling acquired brands to achieve hypergrowth on global digital marketplaces.

Wonder Brands partners with successful digital brands in Latin America, investing significantly to boost growth. It provides value through technology, digital marketing, supply chain, administration support, enabling brands to expand reach and diversify products.

Refoxy Pharma develops therapeutic medicines aimed at treating age-related diseases and promoting healthy longevity. The company studies FOXO proteins that regulate genes involved in stress resistance and metabolism, and works on novel modulators of a central stress response pathway to influence aging through genetics, with the goal of extending the years of healthy living for patients.

Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

LEAF4Life develops innovative medicines focused on mitigating threats from dangerous pathogens. Its flagship product is liposomal transcrocetin, designed for treating severe acute respiratory distress syndrome.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

NextMarkets GmbH, founded in 2014 and based in Cologne, Germany, offers a user-friendly web and mobile application tailored for private investors engaging in capital markets. The platform allows users to trade a wide range of financial instruments, including contracts for difference (CFDs) on equities, foreign exchange, bonds, and commodities. Recognizing that a significant majority of private investors struggle in the stock market due to behavioral economic factors, NextMarkets aims to empower its users by providing educational resources, training, and strategies that enhance their trading experience. The company's mission is to promote a more informed and sustainable approach to investing, enabling users to better understand market dynamics and make informed trading decisions.

Cambrian BioPharma specializes in developing innovative therapeutics aimed at extending healthspan, the period of life spent in good health. As a Distributed Development Company (DisCo), it focuses on advancing scientific breakthroughs targeting biological drivers of aging, initially treating specific diseases and later deploying these interventions preventatively to enhance overall quality of life.

Sensei Biotherapeutics is a clinical-stage biotechnology company developing next-generation cancer immunotherapies. It focuses on novel biologics that modulate the immune system to treat cancers with unmet need, using its ImmunoPhage discovery platform to study the tumor microenvironment and identify differentiated mechanisms that engage both innate and adaptive immunity. The company pursues a Tumor Microenvironment Activated Biologics TMAb platform to selectively disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. Headquartered in Gaithersburg, Maryland with an office in Boston, Massachusetts, Sensei Biotherapeutics has four investigational product candidates in development: SNS-101, SNS-102, SNS-103, and SNS-201.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.